| Name | Title | Contact Details |
|---|---|---|
Nancy Saputra |
IT Director, Systems, Cloud, and Information Security | Profile |
Timothy Moore |
Chief Technical Officer | Profile |
Timothy Moore |
Chief Technology Officer | Profile |
Alison Moore |
Chief Technical Officer | Profile |
Alison Moore |
Executive Vice President of Operations and Chief Technical Officer | Profile |
GrowBLOX Sciences (OTCQ GBLX) – merges state-of-the-art technologies in plant biology, cultivation and post-production processes in order to optimize safe, consistent medical Cannabis. The company is pioneering technologies and industry-leading processes in combination with a Big Data-driven clinical research and development program to bring relief to patients in communities across the country.
Good Therapeutics is an early-stage biotechnology company based in Seattle, Washington. We are developing "context-dependent" protein drugs that sense biomarkers and respond with a therapeutic activity. Our goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy.
Trident Health is the leading provider of laboratory and mobile imaging services to the long term care community in the US. Operating in 43 states, we currently provide these services to more than 5,000 of the 16,000+ long term care facilities in the US.
Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna`s proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions.
NanoCellect`s mission is to facilitate biomedical breakthroughs by making cell analysis and sorting technology more affordable and easier to use. Our microfluidic flow cytometry platforms enable biomedical scientists to analyze and sort cells required for drug discovery, diagnostics, and basic research. The company was founded in late 2009 as a spinout from UCSD and dedicated 6 years developing the foundation of the WOLF`s technology before launching the WOLF (our first product) in 2016. Initial funding of R&D was graciously funded by multiple NIH SBIR grants and contracts and recently backed by FusionX Ventures and other private investors.